RxSight Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-48.61	-66.76	-48.69	3.37	26.13
Depreciation & Amortization	4.24	4.02	3.99	4.01	3.93
Share-Based Compensation	15.75	11.4	7.58	4.19	4.6
Other Operating Activities	-12.97	-7.51	-7.58	-70.98	-175.37
Operating Cash Flow	-41.59	-58.85	-44.71	-35.2	-40.62
Capital Expenditures	-4.81	-2.39	-1.94	-2.54	-3.48
Change in Investments	-17.32	42.34	-79.97	18.13	-2.39
Investing Cash Flow	-22.13	39.95	-81.91	15.59	-5.87
Share Issuance / Repurchase	105.96	7.83	121.14	0.99	1.52
Debt Issued / Paid	-42.39	-0.27	14.84	24.17	-0.19
Other Financing Activities	-2.05	-1.23	1.37	0.07	-
Financing Cash Flow	61.52	6.33	137.34	25.24	1.33
Exchange Rate Effect	0.01	-0.01	-0.01	0	0.01
Net Cash Flow	-2.19	-12.58	10.72	5.63	-45.15
Free Cash Flow	-46.41	-61.24	-46.65	-37.74	-44.1
Free Cash Flow Margin	-52.10%	-124.97%	-206.47%	-257.11%	-1967.96%
Free Cash Flow Per Share	-1.35	-2.21	-3.42	-10.18	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).